A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Stem Cell Transplant is Not Planned as Initial Therapy

Estado	**Tipo de Participantes**	**Rangos de Edad**
Fin Reclutamiento	No aportado	Mayores de 64 , Adultos (18-64 años)
Género	**Fases**	**Participantes esperados**
Ambos	Fase III	250
Resultados	**Bajo nivel intervención**	**Enfermedad rara**
Sin resultados	No	Si
Cobertura geográfica	**Ámbitos del ensayo**	**Terapia avanzada**
Sin determinar	seguridad, eficacia, farmacocinética, farmacodinamica	NO

Información

Identificador
2023-505850-16-00 (CTIS)

Cod. Protocolo
68284528MMY3004

Transicionado 2021-001242-35

Área terapéutica
Enfermedades [C] - Cáncer [C04]|

Enfermedad investigada
Multiple Myeloma

Título Científico

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.

Justificación

No aportado

Objetivo Principal

To compare the efficacy of bortezomib, lenalidomide, and dexamethasone (VRd) induction followed by a single administration of cilta-cel versus VRd induction followed by lenalidomide and dexamethasone (Rd) maintenance in terms of progression-free survival (PFS).

Variables de Evaluación Primaria

Progression-free survival (PFS) with progression defined by IMWG criteria, or death, whichever occurred first.

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

No aportado

Variables de Evaluación Secundaria

No aportado

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

1. 18 years of age 2. Documented diagnosis of MM according to IMWG diagnostic criteria 3. Measurable disease at

Screening 4. Not considered for high-dose chemotherapy with autologous stem cell transplant (ASCT) 5. Eastern Cooperative Oncology Group Performance Status grade of 0 or 1 Contraceptive/Barrier Requirements 6. A woman of childbearing potential (WOCBP) must have 2 negative highly sensitive serum or urine pregnancy test (beta-human chorionic gonadotropin) tests prior to starting VRd and must agree to further testing during the study. 7. When a woman is of childbearing potential, the participant must commit either to abstaining continuously from heterosexual intercourse or agree to practice 2 methods of reliable birth control simultaneously, ie, one highly effective method of contraception (failure rate of <1% per year when used consistently and correctly; see examples below) and one other effective method (ie, male latex or synthetic condom, diaphragm, or cervical cap). 8. A man must commit either to abstaining continuously from heterosexual intercourse or a man Who is sexually active with a WOCBP or a pregnant woman must agree to use a barrier method of contraception (eg, latex or synthetic condom with spermicidal foam/gel/film/cream/suppository), without interruption, from the time of signing the informed consent form (ICF) until at least 4 weeks after the last dose of lenalidomide, 3 months after the last dose of bortezomib, 1 year after receiving the conditioning regimen (cyclophosphamide and fludarabine) or 1 year after receiving cilta-cel infusion (whichever is later), even if they have undergone a successful vasectomy. Should agree to practice contraception according to and for the time frame specified in the global REVLIMID® (or generic lenalidomide) pregnancy prevention program or equivalent local REVLIMID® (or generic lenalidomide) pregnancy prevention program, whichever is more stringent. 9. Women and men must agree not to donate eggs (ova, oocytes) or sperm, respectively, during the study and until at least 4 weeks after the last dose of lenalidomide, 3 months after the last dose of bortezomib, 1 year after receiving the conditioning regimen (cyclophosphamide and fludarabine), or 1 year after receiving cilta-cel infusion (whichever is later).

Criterios de Exclusión

1. Frailty index of 2 according to Myeloma Geriatric Assessment score 10. Hepatitis B infection. In the event the infection status is unclear, quantitative levels are necessary to determine the infection status. 11. Hepatitis C infection (defined as anti-hepatitis C virus [HCV] antibody positive or detectable HCV-RNA) or known to have a history of hepatitis C. 12. Participant must not require continuous supplemental oxygen. 13. Contraindications, known life-threatening allergies, hypersensitivity, or intolerance to any of the study treatments, including cyclophosphamide or fludarabine (if known) or any of their excipients, including boron, mannitol, dimethyl sulfoxide. 14. Serious underlying medical condition, such as: Evidence of active viral or bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic fungal infection Active autoimmune disease Overt clinical evidence of dementia or altered mental status Any history of Parkinson's disease or other neurodegenerative disorder Prior/Concomitant Medications. 15. Prior treatment with CAR-T therapy directed at any target. 16. Any therapy that is targeted to BCMA. 17. Any prior therapy for MM or smoldering myeloma other than a short course of corticosteroids and/or maximum 1 cycle of VRd therapy prior to enrollment. Radiation therapy for treatment of plasmacytoma within 14 days before enrollment (palliative radiation for pain control secondary to lytic lesion is allowed within 14 days of enrollment). However, if the radiation portal covered 5% of the bone marrow reserve, the subject is eligible irrespective of the end date of radiation therapy. 2. Active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. 3.Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5. 4. The following cardiac conditions: New York Heart Association Stage III or IV congestive heart failure Myocardial infarction or coronary artery bypass graft 6 months prior to enrollment History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration History of severe non-ischemic cardiomyopathy Screening 12-lead ECG showing a baseline corrected Prolonged corrected QT interval (QTc) >470 msec (for women) and >450 msec (for men), as assessed by 12-lead ECG, except in participants with a pacemaker. Impaired cardiac function (left ventricular ejection fraction <45%) as assessed by echocardiogram or multiple-gated acquisition (MUGA) scan. 5. Known active, or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. 6.Stroke or seizure within 6 months of signing ICF. 7.Plasma cell leukemia at the time of screening (>2.0 x 10^9/L plasma cells by standard differential), Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary amyloid light-chain amyloidosis. 8. Seropositive for human immunodeficiency virus (HIV). 9. Vaccinated with live, attenuated vaccine within 4 weeks prior to first dose of VRd.

Calendario

(Última actualización: 13/01/2026)

Autorización	Inicio de Ensayo	Inclusión Primer Paciente	Interrumpido	Reiniciado
11/08/2021	05/08/2021	19/08/2021	No aportado	No aportado

Fin de reclutamiento	Fin prematuro (España)	Fin prematuro (Global)	Fin del ensayo en España	Fin del ensayo global
03/12/2023	No aportado	No aportado	No aportado	No aportado

Promotor

Janssen - Cilag International Belgium

Turnhoutseweg 30

Contact Person

CTIS Point of Contact

+31717996133

CTISadmin@its.jnj.com

Monetary support: N/A

Tipo de promotor: Comercial

Ceim

CEIm de la Comunidad Foral de Navarra

C/ Irunlarrea, 3 31008 Pamplona

ceic@cfnavarra.es

Centros

Activo (03/11/2021)

CLINICA UNIVERSIDAD DE NAVARRA

Pamplona/Iruña

NAVARRA

Activo (19/08/2021)

HOSPITAL CLINICO UNIVERSITARIO DE SALAMANCA (COMPLEJO ASISTENCIAL UNIV.SA)

Salamanca

SALAMANCA

Activo (09/02/2022)

HOSPITAL CLINICO UNIVERSITARIO VIRGEN DE LA ARRIXACA

Murcia

MURCIA

Activo (16/03/2022)

HOSPITAL DE LA SANTA CREU I SANT PAU

Barcelona

BARCELONA

No iniciado (--/--/----)

Hospital De La Santa Creu I Sant Pau

Barcelona

BARCELONA

Hematology

No iniciado (--/--/----)

Hospital General Universitario Gregorio Maranon

Madrid

MADRID

Hematology

Activo (17/09/2021)

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON

Madrid

MADRID

Activo (21/12/2021)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

Activo (03/12/2021)

HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA

Santander

CANTABRIA

Activo (23/03/2022)

HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO

Sevilla

SEVILLA

Activo (14/12/2021)

HOSPITAL UNIVERSITARIO Y POLITECNICO LA FE

València

VALENCIA

Activo (15/10/2021)

HOSPITAL UNIVERSITARIO 12 DE OCTUBRE

Madrid

MADRID

Activo (07/02/2022)

Institut Catala D'oncologia

Hospitalet de Llobregat, L'

BARCELONA

Medicamentos

Lenalidomide Mylan 25 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Mylan 15 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Accord 20 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Accord 25 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Accord 2.5 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Accord 15 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Accord 5 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Mylan 5 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Mylan 20 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Mylan 2.5 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Accord 5 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Mylan 10 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Dexamethasone Tablets BP 2.0mg
TABLET
ORAL USE

Código ATC: H02AB02 - DEXAMETASONA
Principios Activos: N/A

Experimental

Lenalidomide Accord 10 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Mylan 25 mg hard capsules
CAPSULE, HARD
ORAL USE

Fortecortin® 2 mg Tabletten
TABLET
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Código ATC: H02AB02 - DEXAMETASONA
Principios Activos: N/A

Experimental

Lenalidomide Accord 20 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

-

-
INTRAVENOUS USE

Código ATC: L01BB05 - FLUDARABINA
Principios Activos: N/A

Experimental

Lenalidomide Mylan 10 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Mylan 2.5 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

CARVYKTI 3.2 × 10^6 1.0 × 10^8 cells dispersion for infusion

DISPERSION FOR INFUSION
INTRAVENOUS USE

Código ATC: L01XL05 - CILTACABTAGEN AUTOLEUCEL
Principios Activos: N/A

Huérfano

Experimental

Lenalidomide Accord 10 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Mylan 5 mg hard capsules

CAPSULE, HARD
ORAL USE

Lenalidomide Mylan 15 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

-
-
INTRAVENOUS USE

Código ATC: L01AA01 - CICLOFOSFAMIDA
Principios Activos: N/A

Experimental

Lenalidomide Accord 25 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Accord 2.5 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Lenalidomide Mylan 20 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Dexamethason 4 mg JENAPHARM®
TABLET
ORAL

Código ATC: H02AB02 - DEXAMETASONA
Principios Activos: N/A

Experimental

VELCADE 3.5 mg powder for solution for injection
SOLUTION FOR INJECTION
SUBCUTANEOUS USE

Código ATC: L01XG01 - BORTEZOMIB
Principios Activos: N/A

Experimental

Lenalidomide Accord 15 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

Sin resultados

A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Stem Cell Transplant is Not Planned as Initial Therapy

State	Type of participants	Age Ranges
End of recruitment	Not provided	Older than 64 , Adults (18-64 years)
Gender	**Phases**	**Expected Participants**
Both	Phase III	250
Results	**Low level of intervention**	**Rare disease**
No results	No	Yes
Geographic coverage	**Areas of the study**	**Advanced therapy**
Undetermined	safety, effectiveness, pharmacokinetics, pharmacodynamics	NO

Information

Identifier
2023-505850-16-00 (CTIS)

Protocol Code
68284528MMY3004

Transitioned 2021-001242-35

Therapeutic area
Diseases [C] - Cancer [C04]|

Investigated Disease
Multiple Myeloma

Scientific Title

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.

Rationale

Not provided

Main Objective

To compare the efficacy of bortezomib, lenalidomide, and dexamethasone (VRd) induction followed by a single administration of cilta-cel versus VRd induction followed by lenalidomide and dexamethasone (Rd) maintenance in terms of progression-free survival (PFS).

Primary Endpoints

Progression-free survival (PFS) with progression defined by IMWG criteria, or death, whichever occurred first.

Temporary moments of secondary assessment

Not provided

Secondary Objective

Not provided

Secondary Endpoints

Not provided

Temporary moments of secondary assessment

Not provided

Inclusion criteria

1. 18 years of age 2. Documented diagnosis of MM according to IMWG diagnostic criteria 3. Measurable disease at

Screening 4. Not considered for high-dose chemotherapy with autologous stem cell transplant (ASCT) 5. Eastern Cooperative Oncology Group Performance Status grade of 0 or 1 Contraceptive/Barrier Requirements 6. A woman of childbearing potential (WOCBP) must have 2 negative highly sensitive serum or urine pregnancy test (beta-human chorionic gonadotropin) tests prior to starting VRd and must agree to further testing during the study. 7. When a woman is of childbearing potential, the participant must commit either to abstaining continuously from heterosexual intercourse or agree to practice 2 methods of reliable birth control simultaneously, ie, one highly effective method of contraception (failure rate of <1% per year when used consistently and correctly; see examples below) and one other effective method (ie, male latex or synthetic condom, diaphragm, or cervical cap). 8. A man must commit either to abstaining continuously from heterosexual intercourse or a man Who is sexually active with a WOCBP or a pregnant woman must agree to use a barrier method of contraception (eg, latex or synthetic condom with spermicidal foam/gel/film/cream/suppository), without interruption, from the time of signing the informed consent form (ICF) until at least 4 weeks after the last dose of lenalidomide, 3 months after the last dose of bortezomib, 1 year after receiving the conditioning regimen (cyclophosphamide and fludarabine) or 1 year after receiving cilta-cel infusion (whichever is later), even if they have undergone a successful vasectomy. Should agree to practice contraception according to and for the time frame specified in the global REVLIMID® (or generic lenalidomide) pregnancy prevention program or equivalent local REVLIMID® (or generic lenalidomide) pregnancy prevention program, whichever is more stringent. 9. Women and men must agree not to donate eggs (ova, oocytes) or sperm, respectively, during the study and until at least 4 weeks after the last dose of lenalidomide, 3 months after the last dose of bortezomib, 1 year after receiving the conditioning regimen (cyclophosphamide and fludarabine), or 1 year after receiving cilta-cel infusion (whichever is later).

Exclusion criteria

1. Frailty index of 2 according to Myeloma Geriatric Assessment score 10. Hepatitis B infection. In the event the infection status is unclear, quantitative levels are necessary to determine the infection status. 11. Hepatitis C infection (defined as anti-hepatitis C virus [HCV] antibody positive or detectable HCV-RNA) or known to have a history of hepatitis C. 12. Participant must not require continuous supplemental oxygen. 13. Contraindications, known life-threatening allergies, hypersensitivity, or intolerance to any of the study treatments, including cyclophosphamide or fludarabine (if known) or any of their excipients, including boron, mannitol, dimethyl sulfoxide. 14. Serious underlying medical condition, such as: Evidence of active viral or bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic fungal infection Active autoimmune disease Overt clinical evidence of dementia or altered mental status Any history of Parkinson's disease or other neurodegenerative disorder Prior/Concomitant Medications. 15. Prior treatment with CAR-T therapy directed at any target. 16. Any therapy that is targeted to BCMA. 17. Any prior therapy for MM or smoldering myeloma other than a short course of corticosteroids and/or maximum 1 cycle of VRd therapy prior to enrollment. Radiation therapy for treatment of plasmacytoma within 14 days before enrollment (palliative radiation for pain control secondary to lytic lesion is allowed within 14 days of enrollment). However, if the radiation portal covered 5% of the bone marrow reserve, the subject is eligible irrespective of the end date of radiation therapy. 2. Active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. 3.Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5. 4. The following cardiac conditions: New York Heart Association Stage III or IV congestive heart failure Myocardial infarction or coronary artery bypass graft 6 months prior to enrollment History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration History of severe non-ischemic cardiomyopathy Screening 12-lead ECG showing a baseline corrected Prolonged corrected QT interval (QTc) >470 msec (for women) and >450 msec (for men), as assessed by 12-lead ECG, except in participants with a pacemaker. Impaired cardiac function (left ventricular ejection fraction <45%) as assessed by echocardiogram or multiple-gated acquisition (MUGA) scan. 5. Known active, or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. 6.Stroke or seizure within 6 months of signing ICF. 7.Plasma cell leukemia at the time of screening (>2.0 x 10^9/L plasma cells by standard differential), Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary amyloid light-chain amyloidosis. 8. Seropositive for human immunodeficiency virus (HIV). 9. Vaccinated with live, attenuated vaccine within 4 weeks prior to first dose of VRd.

Calendar

(Last Update: 13/01/2026)

Authorization	Start of Trial	First patient inclusion	Halted	Restarted
11/08/2021	05/08/2021	19/08/2021	Not aported	Not aported

End of recruitment	Premature end (Spain)	Premature End (Global)	Trial end (Spain)	Trial end (Global)
03/12/2023	Not aported	Not aported	Not aported	Not aported

Sponsor

Janssen - Cilag International Belgium

Turnhoutseweg 30

Contact Person

CTIS Point of Contact

+31717996133

CTISadmin@its.jnj.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm de la Comunidad Foral de Navarra

C/ Irunlarrea, 3 31008 Pamplona

ceic@cfnavarra.es

Sites

Active (03/11/2021)

CLINICA UNIVERSIDAD DE NAVARRA

Pamplona/Iruña

NAVARRA

Active (19/08/2021)

HOSPITAL CLINICO UNIVERSITARIO DE SALAMANCA (COMPLEJO ASISTENCIAL UNIV.SA)

Salamanca

SALAMANCA

Active (09/02/2022)

HOSPITAL CLINICO UNIVERSITARIO VIRGEN DE LA ARRIXACA

Murcia

MURCIA

Active (16/03/2022)

HOSPITAL DE LA SANTA CREU I SANT PAU

Barcelona

BARCELONA

not initialized (--/--/----)

Hospital De La Santa Creu I Sant Pau

Barcelona

BARCELONA

Hematology

not initialized (--/--/----)

Hospital General Universitario Gregorio Maranon

Madrid

MADRID

Hematology

Active (17/09/2021)

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON

Madrid

MADRID

Active (21/12/2021)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

Active (03/12/2021)

HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA

Santander

CANTABRIA

Active (23/03/2022)

HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO

Sevilla

SEVILLA

Active (14/12/2021)

HOSPITAL UNIVERSITARIO Y POLITECNICO LA FE

València

VALENCIA

Active (15/10/2021)

HOSPITAL UNIVERSITARIO 12 DE OCTUBRE

Madrid

MADRID

Active (07/02/2022)

Institut Catala D'oncologia

Hospitalet de Llobregat, L'

BARCELONA

Medication

Lenalidomide Mylan 25 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Lenalidomide Mylan 15 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Lenalidomide Accord 20 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Lenalidomide Accord 25 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Lenalidomide Accord 2.5 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Lenalidomide Accord 15 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Lenalidomide Accord 5 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Lenalidomide Mylan 5 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Lenalidomide Mylan 20 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Lenalidomide Mylan 2.5 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Lenalidomide Accord 5 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Lenalidomide Mylan 10 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Dexamethasone Tablets BP 2.0mg
TABLET
ORAL USE

ATC code: H02AB02 - DEXAMETASONA
Active Principles: N/A

Experimental

Lenalidomide Accord 10 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Lenalidomide Mylan 25 mg hard capsules
CAPSULE, HARD
ORAL USE

Fortecortin® 2 mg Tabletten
TABLET
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A
Experimental

ATC code: H02AB02 - DEXAMETASONA
Active Principles: N/A
Experimental

Lenalidomide Accord 20 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A
Experimental

-
-
INTRAVENOUS USE

ATC code: L01BB05 - FLUDARABINA
Active Principles: N/A
Experimental

Lenalidomide Mylan 10 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A
Experimental

Lenalidomide Mylan 2.5 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A
Experimental

CARVYKTI 3.2 × 10^6 1.0 × 10^8 cells dispersion for infusion
DISPERSION FOR INFUSION
INTRAVENOUS USE

ATC code: L01XL05 - CILTACABTAGEN AUTOLEUCEL
Active Principles: N/A
Orphan
Experimental

Lenalidomide Accord 10 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A
Experimental

Lenalidomide Mylan 5 mg hard capsules
CAPSULE, HARD
ORAL USE

Lenalidomide Mylan 15 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

-
-
INTRAVENOUS USE

ATC code: L01AA01 - CICLOFOSFAMIDA
Active Principles: N/A

Experimental

Lenalidomide Accord 25 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Lenalidomide Accord 2.5 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Lenalidomide Mylan 20 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

Dexamethason 4 mg JENAPHARM®
TABLET
ORAL

ATC code: H02AB02 - DEXAMETASONA
Active Principles: N/A

Experimental

VELCADE 3.5 mg powder for solution for injection
SOLUTION FOR INJECTION
SUBCUTANEOUS USE

ATC code: L01XG01 - BORTEZOMIB
Active Principles: N/A

Experimental

Lenalidomide Accord 15 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

No results